The sizable yield comes with a concerning footnote. Just look at the rest of the story.

Shares of multiple companies including MRF, Honeywell Automation, Shree Cement, Cummins India, and Pfizer will trade ...

Pfizer (NYSE:PFE) has announced a new CFO transition as Dave Denton prepares to step down in August, adding another management change at a time when the drugmaker is still working to rebuild growth ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

Pfizer (NYSE: PFE) shares gained 2.8% through 11:15 a.m. ET Thursday, and investors can thank the friendly bankers at RBC Capital Markets for that. This morning, RBC removed its sell rating from ...

Pfizer Inc. secures Metsera, Inc. acquisition, outbidding Novo Nordisk, with a deal valued up to $86.25 per share including milestone CVRs. The board favored PFE's offer due to higher certainty of ...

Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals.

Shares of Pfizer, Inc. (NASDAQ: PFE) are trading higher after a study found that the company’s new mRNA flu vaccine outperforms traditional shots against predominant strains. What To Know: A study ...

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues. The big US drugmaker pointed to another drop in ...